Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis

Table 1 Baseline characteristics of patients

	Ipilimumab induced enterocolitis	Ipilimumab without enterocolitis
Demographics
Total number of patients	16	98
Mean age in years	63	61
Female sex, n (%)	8 (50)	28 (29)
Laboratory characteristics prior to ipilimumab
Mean white blood cell count, cells/cu. mm (range)	6720 (3510-17100)	7530 (1080-25800)
Reference range 4500-11000 cells/cu. mm
Mean lymphocyte count, cells per cu. mm (range)	1570 (592-4610)	1440 (97-4420)
Reference range 1150-4800 cells/cu. mm
Mean neutrophil count, cells per cu. mm (range)	4350 (2040-11610)	5200 (668-23500)
Reference range 1800-7000 cells/cu. mm

Table 2 Clinical features and treatment of 16 patients with ipilimumab-mediated enterocolitis n (%)

Onset of diarrhea
After 1 dose of ipilimumab	3 (19)
After 2 doses of ipilimumab	7 (43)
After 3 doses of ipilimumab	3 (19)
After 4 doses of ipilimumab	3 (19)
Diarrhea details
Number of bowel movements/day, median (range)	6 (5-12)
Grade 2 diarrhea	9 (56)
Grade 3 diarrhea	7 (44)
Grade 4/5 diarrhea	0
Associated symptoms
Abdominal pain	10 (63)
Nausea or vomiting	3 (19)
Fever	2 (13)
Anorexia	2 (13)
Endoscopic findings
Mucosal erythema, edema, or erosions only	6 (43)
Ulcers	8 (57)
Treatment of diarrhea
High dose corticosteroids	16 (100)
Infliximab	9 (56)